Gene Therapies Market Will Generate $204m In 2020, According To New Visiongain Analysis

12 September 2018

A new report by visiongain forecasts the world gene therapy industry will achieve revenues of $204m in 2020, with potential to multiply further in sales to 2026. Those revenues will expand from 2016 to 2026 as new genetic treatments reach the market and develop that industry. That prediction and others appear in Gene Therapy R&D and Revenue Forecasts 2016-2026: Prospects for Drugs Treating Cancer, Cardiovascular Disorders, Eye Conditions, Rare Diseases and Other Needs.

Visiongain, a business information publisher and consultancy in London, UK, releases that study in January 2016. That survey analyses events, prospects and opportunities shaping the development, production and sale of genetic treatments. The new analysis shows multilevel revenue forecasting, qualitative analyses and interviews. It also assesses leading companies – their products, strategies and R&D. Visiongain’s purpose is to help organisations explore the potentials of industries and markets.

Gene therapy involves the administration of a gene to treat a disease. Those treatments aim to be delivered only once or a few times rather than as a medicine administered long-term. Gene therapies could potentially cure a disease using methods such as adding a gene, correcting it, or using genetic material to cause cell death. That emerging market has attracted interest from pharma companies big and small, a trend likely to continue. Visiongain predicts expansion in gene therapy revenues from 2016 to 2026, building upon the extensive research and development in that biotechnological field. That medicine holds great promise for pharma companies and patients, the new study explains.

In 2015, the cancer treatment submarket formed the most lucrative part of that industry. However that segment will shift in market share from 2016 to 2026 and lose a large percentage of its market share to the rare disease treatment submarket and the cardiovascular disease submarket. That trend will result from the rare disease pipeline and cardiovascular disorder pipeline launching their treatments first as their pipeline candidates are later in development. Gene therapies in development will bring in a new era for disease treatment and make a difference in long-term benefits for patients.

Mashael Zaidi, a pharmaceutical industry analyst in visiongain, said: “The gene therapy market is currently at a pivotal point in its development, with new treatments set to reach a market that has yet to establish itself. A lot of the success of this market will depend on the decisions made now on issues such as pricing, reimbursement and regulations. Gene therapy must gain acceptance from cautious regulators, potential users and payers by not only proving its efficacy and safety, but dealing with issues of cost. In the past ethics has been a controversial topic for gene therapy and will continue to affect its potential.”

In this report visiongain defines gene therapy products as those that modify the expression of particular genes or that correct abnormal genes. Therefore this study excludes a number of products that may be considered as gene therapies, but only under wider definitions, such as gene silencing and oligonucleotide therapies, antisense therapy and treatments that boost the immune response.

Visiongain’s new investigation shows revenue predictions to 2026 for gene therapy at overall world market, submarket and product level. First it forecasts the following five therapeutic applications at world level to 2026:

• Cancer (oncology)
• Cardiovascular diseases
• Ophthalmological disorders
• Rare medical conditions, including inherited and hard-to-treat disorders
• Other applications of that biotechnology in human healthcare.

That study next forecasts revenues of two marketed products to 2026:

• Glybera
• Neovasculgen.

The report also discusses these brands: Gendicine and Oncorine. In addition the investigation gives 12 discussions for leading compounds in development, including revenue forecasting to 2026 for these six drug candidates:

• GSK2696273 (GSK)
• Collategene/AMG0001 (AnGes MG/Vical)
• BC-819 (BioCancell)
• Lenti-D (Bluebird Bio)
• SPK-RPE65 (Spark Therapeutics)
• Invossa/TissueGene-C (TissueGene/Kolon Life Science).

That work examines leading countries, assessing regulations and other forces affecting gene therapy, especially in the United States, the European Union and Japan. The study also shows interviews with Lysogene, Cell Therapy Catapult and the Human Stem Cells Institute.

Visiongain’s new survey also explores leading companies. That investigation discusses acquisitions, other deals, collaborations and R&D. Organisations discussed include these:

• Bristol-Myers Squibb
• Pfizer
• Bayer Healthcare
• Novartis
• uniQure
• Biogen
• Bluebird Bio
• Spark Therapeutics.

Gene Therapy and Revenue Forecasts 2016-2026: Prospects for Drugs Treating Cancer, Cardiovascular Disorders, Eye Conditions, Rare Diseases and Other Needs adds to visiongain’s reports on industries and markets in healthcare. That portfolio covers pharmaceuticals, biotechnology, medical devices, diagnostics and outsourced services.

Recent News

Visiongain Publishes Influenza Vaccines Market Report 2020-2030

For the companies operating in the global influenza vaccines market, there is an immense opportunity from emerging economies across the globe.

30 September 2020


Visiongain Publishes Next-Generation Pharmaceutical Temperature Management Solutions Market Report 2020-2030

Maintaining the quality and safety of the product in the supply chain has always been a high priority for pharmaceutical companies. New market dynamics including an evolving product line, more stringent regulations, geographically connected supply chains, rising risk, and extreme cost pressure have raised stakes significantly.

28 September 2020


Visiongain Publishes OTC Drugs & Dietary Supplements Market Report 2020-2030

The increasing rates of patent expiry lead to a counter-strategy of switching companies from Rx to OTC. In the US, according to the Consumer Healthcare Products Association, approximately 106 ingredients and dosage strengths have undergone a change from Rx to OTC to around 700 OTC products on the market.

23 September 2020


Visiongain Publishes Healthcare Cold Chain Logistics Market Report 2020-2030

. The growth of this market is majorly driven by increasing sales of temperature sensitive pharmaceutical products, longer life expectancy and rising geriatric population are some of the prominent factors.

16 September 2020